37 results about "Malignant Solid Neoplasm" patented technology

The invention relates to treatment on human malignant solid tumor by HNF4 alpha inducement and differentiation, in particularly to a method for utilizing Hepatocyte Neclear Factor-4 alpha (HNF4 alpha) to induce the differentiation of the human malignant solid tumor so as to be applied to the treatment on the malignant solid tumor and application thereof. The research shows that the modulation of gene expression of the HNF4 alpha of malignant solid tumor cells can effectively produce functions of the inducement and the differentiation on the tumor cells so as to provide a new treatment means for inducing and differentiating the tumor.

Use of hepatocyte nuclear factor 4α (HNF4α) for the treatment of human malignant solid tumors through induction-differentiation therapy is provided.

The invention provides construction and application of a fourth-generation chimeric antigen receptor T (CAR-T) cell (expressing IL-7 and CCL19) specific to Nectin-4 dual targets on the surface of a malignant tumor. Two spatial epitopes of a Nectin-4 antigen are taken as target points, and the constructed fourth-generation CAR-T is used for treating and expressing a malignant solid tumor of the Nectin-4 antigen to solve the immune escape problem of the CAR-T during treatment of the solid tumor; and the constructed fourth-generation CAR-T can enhance proliferative capacity and sustained survivability, so that the solid tumor is effectively treated, and a new strategy is provided for effective prevention and treatment of postoperative recurrence / metastasis of the solid tumor.

A method of treating a malignant solid tumor in a subject is disclosed herein. The method includes the steps of administering to the subject an immunomodulatory dose of a radiohalogenated compound that is differentially taken up by and retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by intratumorally injecting into (or treating via a separate method) at least one of the malignant solid tumors a composition that includes one or more agents capable of stimulating specific immune cells within the tumor microenvironment. In certain exemplary embodiments, the radiohalogenated compound has the formula:wherein R1 is a radioactive halogen isotope, n is 18 and R2 is —N+(CH3)3.

The invention relates to the field of gene therapy and medical diagnosis and provides application of long noncoding RNA HNF1A-AS1 (hepatocyte nuclear factor-1Alpha Antisense 1) in the preparation of drugs for treating human malignant solid tumors. Studying shows that by controlling gene expression of malignant solid tumor cells HNF1A-AS1, proliferation of the malignant solid tumors can be effectively inhibited, and thereby a novel target is provided for the clinical treatment of malignant solid tumors.

An application of the tumor cell nucleus monoantibody as the synergist in physically treating solid tumor by directionally combining with the necrotic tissue of tumor specifically and killing the tumor cells by the nuclein carried by it is disclosed. It features that the normal tissue can not be damaged.

The invention provides a preparation method for extractive originating from an araliaceae plant, notoginseng. The extractive of the category mainly contains extractive of dammarane type, tetracyclic triterpene category, protopanaxadiol type and saponin category, wherein the content of ginsenoside Rb1 and Rd is not lower than 60 percent, and the content of ginsenoside Re, Rg1, and notoginseng saponin R1 is not higher than 5 percent. The notoginseng is extracted by using alcohol containing water as the solvent, chromatography to the extracting solution through a chromatographic column is performed to obtain elutriant, reversed phase and liquid phase gradient elution is performed, the elutriant is collected, and then the target extractive is obtained through concentration. The extraction process of the invention can effectively remove impurities of sugar, protein, amino acid, and the saponin of the protopanaxadiol type of the notoginseng, etc., and improve the content of effective components. The effective components are definite, the process is simple, the quality is controllable, and the invention is suitable for industrialized production, thereby being applied for preparing medicines treating malignant solid tumors.

The invention discloses a eucaryon expression vector of a DNA vaccine and the application. The eucaryon expression vector of DNA vaccine is a recombination pVAX1 eucaryon expression vector which is got by adding the internal ribosome in pVAX1 vector skeleton and entering the site coded sequence. The eucaryon expression vector may show the wide spectrum curing function for breast cancer, pancreatic cancer, restocarcinoma and multi-type malignancy solid tumor, which has good humoral immunity and cell-mediated immunity effect, and inhibits the growth of the tumor.

The present invention provides a kind of anticancer injection containing rabdosia diterpene or its derivative and beta-cyclodextrin or its derivative. The insoluble rabdosia diterpene is first prepared into cyclodextrin inclusion to raise the dissolubility, and then prepared into injection or freeze dried powder for injection. The anticancer injection has high stability, high treating effect on liver cancer, esophageal cancer, gastric cancer and other malignant solid tumors and leukemia, and patient's compliance.

The invention discloses a hydrogen peroxide responsive ratio meter nanoprobe and its use. The nanoprobe comprises a hydrogen peroxide-responsive fluorescent molecule, a hydrogen peroxide-inert fluorescent molecule and a polymer with good biocompatibility. The invention also discloses a use of the hydrogen peroxide responsive ratio meter nanoprobe in preparation of a detection agent of circulatingtumor cells in peripheral blood of malignant solid tumors. The ratio meter nanoprobe has good water solubility, can be easily taken, has low cytotoxicity and can be used for quantitative imaging of hydrogen peroxide in circulating tumor cells. The ratio meter nanoprobe has excellent fluorescence properties, has good sensitivity and specificity to hydrogen peroxide and can detect difference of levels of hydrogen peroxide in malignant solid tumor cells and difference of intracellular intake amounts.

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains for use in a method of treating a malignant solid tumor in a subject.

An application of the toxic histolytic ameba in treating the malignant solid tumor is disclosed, which features that said toxic histolytic ameba is used as the biologic knife to excise malignant solid tumor.

The invention belongs to the field of medical biotechnology, and particularly relates to a genetically modified immune cell with a malignant solid tumor treating function and application thereof. The immune cell is a specific immune cell which is subjected to gene modification so as to over-express lipid metabolism-related genes. The tumor growth inhibiting capacity of the immune cell is realized by reducing accumulation of lipid droplets of the immune cell itself in a tumor microenvironment, reducing expression of tumor promotion genes / protein, and improving the phagocytotic ability, antigen presentation ability and tumor killing ability of the immune cell. The immune cell is an in-vitro NKT cell, a DC cell, a macrophage, a monocyte, a granulocyte or a T cell. Overexpression of related metabolism regulation genes enables the anti-tumor capacity of the immune cell to be improved remarkably. Compared with a chimeric antigen receptor T cell immunotherapy (CAR-T) which receives much attention currently, toxic and side effects are small, cytokine storm can not be caused, and clinical requirements can be met.

The invention relates to a method for treating human malignant solid tumors by using hepatocyte nuclear factor-1alpha (HNF1alpha). Specifically, the invention relates to a method for inducing differentiation of human malignant solid tumor cells by using HNF1alpha, thereby treating malignant solid tumors. The study of the invention shows that tumor cells can be effectively induced to differentiate through regulation of the gene expression of malignant solid tumor cell HNF1alpha, thus providing a new means for induced differentiation therapy of tumors.

The invention provides a method applicable to isolation and introduction of infiltrating T lymphocytes in malignant solid tumors, in particular to comprise procedures as follows: 1) processing a tumortissue into a tissue mass with a volume of 0.5-3 mm<3>; 2) spreading a matrix glue in the cell culture plate and transfer the processed tumor tissue mass in step 1 to the matrix glue for coating; 3)transferring the coated tissue mass in step 2 to another cell culture plate and incubating for 10-60 minutes; 4) adding a pre-amplification medium to the cell culture plate in step 3 and carrying on the pre-amplification culture for 10-30 days and using the semi-liquid of the pre-amplification medium as an exchange per 2-3 days. The invention provides an effective method for isolation and introduction of infiltrating T lymphocytes in tumors for the treatment of specific biotheraphy of malignant solid tumors. The tumor infiltrating T lymphocytes isolated by the method have high purity and stronger killing activity of tumor cells.

The invention relates to application of adult stem cells in treating malignant solid tumors, in particular to application of adult stem cells in preparing a cell preparation for treating malignant solid tumors. The inventor fuses human mesenchymal stem cells and human hemopoietic stem cells respectively with human esophageal carcinoma cells, and injects the fusion cells into SCID (severe combined immune deficiency) / mice and nude mice, and as a result, the emerging rate of tumors of the fusion cells is obviously reduced and the volume thereof is also reduced. The stem cell preparation provided by the invention can obviously inhibit the growth of malignant solid tumors.

The invention discloses a kit for detecting drug resistance of malignant parenchymatous tumors to chemotherapeutic drugs. The kit comprises malignant parenchymatous tumor drug-resistant cell cDNA standard samples, an SYBR Green polymerase chain reaction system, MDR1 and LIMK1 genes for amplification and housekeeping gene primer pairs. When the kit is used, cells of the malignant parenchymatous tumors of a lung cancer and the like are intermittently exposed in vincristine with increasing gradients, and a differential drug-resistant cell substrain is established. It is detected and found through a fluorescent quantitative PCR instrument that expression of the MDR1 gene is enhanced along with increasing of the drug-resistant degree, and expression of the LIMK1 gene is enhanced in cells which have low and moderate resistance to the drugs and retraced in cells which have high resistance to the drugs. Therefore, whether the malignant parenchymatous tumors are resistant to the drugs or not and the drug-resistant degree of the malignant parenchymatous tumors can be diagnosed by jointly detecting expressions of the MDR1 and LIMK1 genes; meanwhile, detection of the expressions of the MDR1 and LIMK1 genes can be used for preparing a chemotherapeutic drug resistance screening preparation, and an accurate therapeutic regimen can be provided for a patient subjected to malignant parenchymatous tumor chemotherapy.

The invention relates to medicine and concerns a method for the poly signal activation of apoptosis of malignant solid tumour cells, carried out by means of the targeted delivery of thallium salts by surface-modified MS2 phage virions which contain a cyclic iRGD ligand that has a high affinity for the integrins avb3 and avb5 and is covalently bound with the shell and with the core, which contains genomic RNA and thallium salts. The invention provides for complex, efficient, prolonged cytotoxic action on focal and metastatic clusters of malignant solid tumour cells, while minimizing undesirable side effects on the healthy cells of an organism.

The invention relates to an ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) method for determining plasma concentration of doxorubicin analogue and metabolite M3 in human plasma and provides a method for determining the concentration of doxorubicin analogue and C13 alcohol metabolite M3 in human plasma through UPLC-MS / MS. The method is carried out with formic acid water-acetonitrile as a mobile phase. The method for detecting the doxorubicin analogue and the metabolite M3 provided by the invention is high in sensitivity and good in repeatability, and can meet the requirements of quantitative analysis of clinical pharmacokinetic biological samples for treating malignant parenchymatous tumors by the doxorubicin analogue.

A use of a hepatocyte nuclear factor 1α gene and / or protein and a recombinant expression vector containing a hepatocyte nuclear factor 1α in preparation of drugs for treating malignant solid tumor diseases and in preparation of differentiation inducing reagents or composition for inducing differentiation of malignant solid tumor cells. The hepatocyte nuclear factor 1α gene can improve the biological properties of tumor cells, and retard the growth of tumor cells, and up-regulation of expression thereof has therapeutic effects on animal models with malignant solid tumors.

The invention discloses an application of beta-dextran in preparation of human dendritic cell tumor vaccine. The application comprises culturing human peripheral blood mononuclear cells with culture medium containing GM-CSF (granulocyte-macrophage colony-stimulating factor) and IL-4 (interleukin-4) to obtain immature human dendritic cell; and inducing loading of tumor antigen onto the immature human dendritic cell through beta-dextran with concentration of 80-120 mug / mL, to obtain human dendritic cell tumor vaccine. According to the invention, the human dendritic cell tumor vaccine is obtained by inducing loading of tumor antigen onto the immature human dendritic cell through beta-dextran. The vaccine can improve immunizing potency of human dendritic cell, promote multiplication capacity of T-cells, especially can externally stimulate the T-cells to achieve specific tumor killing ability, thereby treating various malignant solid tumors.

The invention relates to an ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) method for determining plasma concentration of doxorubicin analogue and metabolite M3 in human plasma and provides a method for determining the concentration of doxorubicin analogue and C13 alcohol metabolite M3 in human plasma through UPLC-MS / MS. The method is carried out with formic acid water-acetonitrile as a mobile phase. The method for detecting the doxorubicin analogue and the metabolite M3 provided by the invention is high in sensitivity and good in repeatability, and can meet the requirements of quantitative analysis of clinical pharmacokinetic biological samples for treating malignant parenchymatous tumors by the doxorubicin analogue.

The invention provides a preparation method for extractive originating from an araliaceae plant, notoginseng. The extractive of the category mainly contains extractive of dammarane type, tetracyclic triterpene category, protopanaxadiol type and saponin category, wherein the content of ginsenoside Rb1 and Rd is not lower than 60 percent, and the content of ginsenoside Re, Rg1, and notoginseng saponin R1 is not higher than 5 percent. The notoginseng is extracted by using alcohol containing water as the solvent, chromatography to the extracting solution through a chromatographic column is performed to obtain elutriant, reversed phase and liquid phase gradient elution is performed, the elutriant is collected, and then the target extractive is obtained through concentration. The extraction process of the invention can effectively remove impurities of sugar, protein, amino acid, and the saponin of the protopanaxadiol type of the notoginseng, etc., and improve the content of effective components. The effective components are definite, the process is simple, the quality is controllable, and the invention is suitable for industrialized production, thereby being applied for preparing medicines treating malignant solid tumors.

Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.

The present invention provides a method for separating and inducing tumor-infiltrating T lymphocytes suitable for malignant solid tumors, specifically, including 1) processing the tumor tissue into a volume of 0.5-3mm 3 2) Matrigel is spread in the cell culture plate, and the tissue piece of the tumor tissue processed in step 1) is transferred to Matrigel for coating; 3) The coated tissue in step 2) Transfer the tissue block to another cell culture plate and incubate for 10-60 minutes; 4) add pre-amplification medium to the cell culture plate in step 3), and carry out pre-amplification culture for 10-30 days, every 2- For 3 days, half of the pre-amplification medium was used to change the medium. The invention provides an effective method for separating and inducing tumor infiltrating T lymphocytes for the specific biological treatment of malignant solid tumors. The tumor infiltrating T lymphocytes separated by the method of the invention have high purity and stronger tumor cell killing activity.

The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.

The invention relates to a natural composition for topical use, such as an ointment, comprising a Lithraea caustica extract and one or more pharmaceutically acceptable innocuous and non-toxic excipients, and to the use thereof in the treatment of benignant, premalignant and malignant solid tumors in the skin, including malignant melanoma. The extract is obtained via extraction with an organic solvent.

Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid metal chelate compound that is differentially retained within malignant solid tumor tissue, and performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or by performing another method of in situ tumor vaccination. In a non-limiting example, the radioactive phospholipid metal chelate compound has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.